Literature DB >> 28255157

Role of High-Mobility Group Box 1 (HMGB1) in Transplantation of Rat Pancreatic Islets.

Seonghee Jeong1, Song Lee1,2, Chan Mee-Lee1, In Kyong Shim2, Song-Cheol Kim3,2,4.   

Abstract

BACKGROUND The potential role of tissue damage factor high-mobility group box 1 (HMGB1) in islet cell transplantation is poorly understood. We investigated the role of HMGB1 in pancreatic islet cell isolation and culture in vitro and after pancreatic islet cell transplantation into diabetic nude mice in vivo. MATERIAL AND METHODS To generate damaged islets, isolated islets were treated with 1 mg/mL lipopolysaccharide (LPS). Some islets were pretreated with a neutralizing anti-HMGB1 antibody before LPS treatment to investigate the effect of HMGB1 on isolated islets damaged by LPS. Cell viability and insulin secretory function were analyzed 48 h after LPS and anti-HMGB1 antibody treatment. Streptozotocin-induced diabetes mice were injected with an anti-HMGB1 antibody 1 h prior to transplantation as a marginal islet mass. After transplantation, blood glucose levels were measured. RESULTS HMGB1 was more abundant in isolated islets than in other tissues, including pancreatic tissue. Anti-HMGB1 antibody pretreatment in LPS-treated islets improved cell viability and insulin secretory function and reduced the production of TNF-α and IL-1β. Streptozotocin-induced diabetic mice treated with an anti-HMGB1 antibody after marginal mass islet cell transplantation recovered to normal blood glucose levels more rapidly and maintained their euglycemic status compared to controls. CONCLUSIONS HMGB1 plays a significant role in early loss of transplanted islet cells. Based on these results, the development of new drugs that inhibit HMGB1 secretion could improve the efficacy and efficiency of clinical islet cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28255157     DOI: 10.12659/aot.900731

Source DB:  PubMed          Journal:  Ann Transplant        ISSN: 1425-9524            Impact factor:   1.530


  2 in total

1.  CORM-2 Pretreatment Attenuates Inflammation-mediated Islet Dysfunction.

Authors:  Xiang-Heng Cai; Guan-Qiao Wang; Rui Liang; Le Wang; Teng-Li Liu; Jia-Qi Zou; Na Liu; Yan Liu; Shu-Sen Wang; Zhong-Yang Shen
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

2.  High Mobility Group Box 1 Contributes to the Acute Rejection of Liver Allografts by Activating Dendritic Cells.

Authors:  Yi Chen; Wenmin Zhang; Hui Bao; Wubing He; Lihong Chen
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.